Multiple Law Firms Seek Regencell Investors Ahead of June Lead-Plaintiff Deadline

Overview

• Three plaintiff firms have issued notices to Regencell Bioscience (NASDAQ: RGC) investors urging those who bought shares between October 28, 2024 and October 31, 2025 to consider moving for lead-plaintiff by June 23, 2026.
• Plaintiffs point to Regencell’s public disclosure of U.S. Department of Justice correspondence and a subpoena about trading as the trigger for suits and say the company’s shares fell sharply after the filings, a decline reported at roughly 18.6 percent.
• Robbins LLP is explicitly investigating allegations that Regencell was affected by a stock manipulation scheme, while other firms describe broader claims that the company failed to disclose vulnerability to manipulation and related regulatory risk.
• The notices offer contingency-fee representation and tools such as portfolio monitoring, and they warn that no class has been certified so investors are not represented by counsel unless they retain one.
• Next steps include competing motions for lead-plaintiff status before the June 23 deadline, an unresolved DOJ inquiry that could prolong or increase legal costs, and potential recovery efforts that would depend on litigation outcomes and any regulatory findings.